Difference between revisions of "Doxorubicin (Adriamycin)"
Jump to navigation
Jump to search
m |
|||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
*[[Acute lymphocytic leukemia]] | *[[Acute lymphocytic leukemia]] | ||
| − | |||
*[[Basal cell and squamous cell skin cancer]] | *[[Basal cell and squamous cell skin cancer]] | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
*[[Bone cancer]] | *[[Bone cancer]] | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
| + | *[[Burkitt lymphoma]] | ||
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
| + | *[[Diffuse large B-cell lymphoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
*[[Hepatobiliary cancer]] | *[[Hepatobiliary cancer]] | ||
| Line 24: | Line 26: | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
*[[Neuroendocrine tumors]] | *[[Neuroendocrine tumors]] | ||
| + | *[[Peripheral T-cell lymphoma]] | ||
| + | *[[Primary mediastinal B-cell lymphoma]] | ||
*[[Renal cancer]] | *[[Renal cancer]] | ||
*[[Sarcoma]] | *[[Sarcoma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| − | |||
*[[Thymoma]] | *[[Thymoma]] | ||
| + | *[[Transformed lymphoma]] | ||
*[[Transplant conditioning regimens]] | *[[Transplant conditioning regimens]] | ||
*[[Uterine cancer]] | *[[Uterine cancer]] | ||
| + | </div> | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 23:01, 4 January 2015
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Basal cell and squamous cell skin cancer
- Bladder cancer
- Bone cancer
- Breast cancer
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Hepatobiliary cancer
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Renal cancer
- Sarcoma
- Small cell lung cancer
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Uterine cancer
Patient drug information
- Doxorubicin (Adriamycin) patient drug information (Chemocare)[3]
- Doxorubicin (Adriamycin) package insert page 1[1]
- Doxorubicin (Adriamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/7/1974: Initial FDA approval
- 5/8/2003: Earliest date with label information at Drugs @ FDA: "Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Also known as
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Adriablastina | Adriacept | Adriacin | Adriamycin HS | Adriamycin PFS | Adriamycin R-D | Adriamycin R.D.F | Adriamycin RDF |
| Adriblastin | Adriblastina | Adriblastina DR | Adriblastina R.D. | Adriblastina R.T.U. | Adriblastina RD | Adriblastina RTU | Adriblastine |
| Adriblastine RTU | Adriblastin PFS | Adriblastin RD | Adricept | Adricin | Adrim | Adrimedac | Adrosal |
| Antraciclin | Biorrub | Biorubina | Cadria | Carcinocin | Cloridrato DE | Doxorrubicina Colhidrol | Daxotel |
| Deldoxin | Dicladox | Dobicin | Dobixin | Doxo | Doxobin | Doxo Cell | Doxocris |
| Doxokebir | Doxolem | Doxolem RU | Doxonolver | Doxor | Doxorrubicina | Doxoruben | Doxorubicina |
| Doxorubicina Asofarma | Doxorubicina Ferrer | Doxorubicina Filaxis | Doxorubicina Gador | Doxorubicina Servycal | Doxorubicina Tedec | Doxorubicin Bigmar | Doxorubicin Comp |
| Doxorubicin DBL | Doxorubicine | Doxorubicin Ebewe | Doxorubicine Bristol | Doxorubicine Dakota | Doxorubicine G GAM | Doxorubicine HCl Eurocept | Doxorubicine Hydrochloride |
| Doxorubicine Sandoz HCl | Doxorubicine Teva | Doxorubicin FOT | Doxorubicin Funk | Doxorubicin HCl | Doxorubicin Hydrochloride | Doxorubicin KMP | Doxorubicin Meda |
| Doxorubicin Pharmachemie | Doxorubicin Teva | Doxorubicinum | Doxorubin | Doxotec | Doxtie | Duxocin | Evacet |
| Farmiblastina | Fauldoxo | Flavicina | hydroxydaunorubicin | Ifadox,L-Doxorubicin | Lipodox | Lyphidox | Myocet |
| Nagun | Neoxane | Nuaze | Oncodria | Onkodox | Onkostatil | Pallagicin | Ranxas |
| Rastocin | Ribodoxo | Ribodoxo-L | Roxorin | Rubex | Trav Doxorubicin | Urokit Doxo Cell Loesung | Varidoxo |
| Zodox | |||||||
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Vesicant chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- Acute lymphocytic leukemia medications
- Aggressive Non-Hodgkin lymphoma medications
- Basal cell and squamous cell skin cancer medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Follicular lymphoma medications
- Hepatobiliary cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Renal cancer medications
- Sarcoma medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Thymoma medications
- Transplant medications
- Uterine cancer medications
- Drugs FDA approved in 1974